Intuitive Surgical enters its Q1 results tonight carrying a 6% weekly loss and a wave of freshly cut price targets — yet the analysts who trimmed are, almost to a firm, keeping their buy-equivalent ratings intact.
The analyst story this week is one of calibration, not conviction loss. In the 48 hours after the last earnings date on April 21, the bulk of the Street moved quickly. Barclays lowered its target to $651 from $712 but kept its Overweight rating. Leerink Partners and Piper Sandler both cut targets — to $573 and $580 respectively — while maintaining Outperform and Overweight calls. Baird was the lone outlier, actually raising its target to $610 from $575. Goldman Sachs had already moved earlier in the month, trimming to $609 from $714 while holding its Buy rating. The pattern is consistent: the consensus mean target sits near $577, implying roughly 27% upside from Wednesday's close of $453.83. Analysts are marking down valuation anchors in a macro-uncertain tape, but none of the bellwether names pulled their positive ratings. The one exception on direction is Mizuho, which held a Neutral at a $525 target — a more cautious outlier in an otherwise bullish lineup.
Positioning in the lending market tells the same relaxed story. Availability is extremely loose, with shares available to borrow running at roughly 680% of current short interest — meaning for every share currently borrowed short, nearly seven more are waiting in the pool. Borrowing costs confirm the lack of squeeze tension: the cost to borrow came in at 0.38% APR as of Tuesday, up about 29% on the week but still far below any level that would constrain new shorts. Short interest itself has eased meaningfully over the past five sessions, falling around 7% to 1.87% of the free float. That's a light level by any standard. The ORTEX short score of 32.8 — running in the mid-30s all week before ticking slightly lower — reflects no particular build of bearish conviction. Any short pressure visible in the price this week looks more like macro risk-off and de-risking into the print than a fundamental short thesis gathering steam.
Options positioning has actually shifted more constructive. The put/call ratio has dropped to 0.87 — well below its 20-day average of 0.93 and sitting at its lowest level of the past year (the 52-week low was 0.82). The z-score of -1.3 indicates call-heavy positioning relative to recent norms, the opposite of what you'd see if traders were aggressively hedging into a feared miss. That tilt toward calls is notable given that the stock is down 6% on the week; options traders appear to be positioning for a recovery rather than bracing for another leg down.
The fundamentals underpinning the Street's optimism are hard to argue with. Q4 revenue came in at $2.77 billion, growing nearly 23% year-on-year, with an EBITDA margin north of 38% and net income margin at nearly 30%. The company carries zero debt and net cash of $4.5 billion. EPS momentum ranks in the 80th percentile on a 30-day view and the 70th percentile over 90 days — a consistent beat record. The bull case centres on the da Vinci installed base topping 10,000 systems globally, with procedure volumes still expanding in both the US and international markets. Bears point to a compressed multiple — the forward P/E on the snapshot data comes in around 42x with an EV/EBITDA near 29x, both contracting modestly over the past month as the stock has given up ground. The newer Dv5 system launch provides an ecosystem refresh catalyst, but convergence between the SP and Ion system utilisation rates is one area the bears flag as a potential growth ceiling.
What to watch in tonight's print: procedure volume growth in international markets and any commentary on Dv5 system placements — the two metrics most likely to determine whether the target reductions this week were pre-emptive prudence or a signal that estimates need a deeper reset.
See the live data behind this article on ORTEX.
Open ISRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
